1. A method for profiling network flows at a measurement point within a computer network, the method comprising:
measuring network flows having invariant features at a measurement point located within routing infrastructure of the computer network to obtain flow statistics; and
aggregating the flow statistics to obtain a traffic profile of the network flows at the measurement point wherein the step of aggregating is based on at least one of the invariant features and wherein the at least one invariant feature is either a source endpoint or a destination endpoint and wherein the step of aggregating is based on distance of the measurement point from the endpoint so that the network flow is profiled at the measurement point within the routing infrastructure in proportion to the distance from the measurement point to the endpoint.
2. The method as claimed in claim 1 wherein the invariant features include source and destination endpoints.
3. The method as claimed in claim 2 further comprising identifying typical traffic source and destination pairs for network flows that transit the measurement point based on the source and destination endpoints.
4. The method as claimed in claim 2 wherein the invariant features include protocol type.
5. The method as claimed in claim 4 wherein the invariant features include port information.
6. The method as claimed in claim 1 wherein the step of aggregating is based on temporal, static network and dynamic routing parameters.
7. The method as claimed in claim 1 further comprising identifying desired network flow characteristics based on dynamic routing and topology information.
8. The method as claimed in claim 1 wherein the computer network is the Internet.
9. A system for profiling network flows at a measurement point within a computer network, the system comprising:
means for measuring network flows having invariant features at a measurement point located within routing infrastructure of the computer network to obtain flow statistics; and
means for aggregating the flow statistics to obtain a traffic profile of the network flows at the measurement point wherein the flow statistics are aggregated based on at least one of the invariant features and wherein the at least one invariant feature is either a source endpoint or a destination endpoint and wherein the flow statistics are aggregated based on distance from the measurement point to the endpoint.
10. The system as claimed in claim 9 wherein the invariant features include source and destination endpoints.
11. The system as claimed in claim 10 further comprising means for identifying typical traffic source and destination pairs for network flows that transit the measurement point based on the source and destination endpoints.
12. The system as claimed in claim 10 wherein the invariant features include protocol type.
13. The system as claimed in claim 12 wherein the invariant features include port information.
14. The system as claimed in claim 9 wherein the flow statistics are aggregated based on temporal, static network and dynamic routing parameters.
15. The system as claimed in claim 9 further comprising means for identifying desired network flow characteristics based on dynamic routing and topology information.
16. The system as claimed in claim 9 wherein the computer network is the Internet.
17. The method as claimed in claim 1 wherein level of route aggregation is a measure of the distance.
18. The method as claimed in claim 1 further comprising utilizing physical and logical router interfaces at a highest level of aggregation.
19. The method as claimed in claim 1 wherein the distance is a logical distance with respect to forwarding topology.
20. The system as claimed in claim 9 wherein the system is capable of adapting to system resources in a dynamic fashion by reassignment of system resources to deal with possible aggregation levels.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A therapeutic agent for dental diseases, which comprises, as an active ingredient, a substance inhibiting the binding between parathyroid hormone related peptide (PTHrP) and a receptor thereof.
2. The therapeutic agent according to claim 1, wherein the dental disease is at least one member selected from a group consisting of abnormal calcification on dentin andor dental pulp, thinning of dentin, basophilic dentin, dentin dysplasia, and dentinogenesis imperfecta.
3. The therapeutic agent according to claim 1 or 2, wherein the substance is an antagonist for the PTHrP receptor.
4. The therapeutic agent according to claim 1 or 2, wherein the substance is an anti-PTHrP antibody.
5. The therapeutic agent according to claim 1 or 2, wherein the substance is a fragment of an anti-PTHrP antibody andor a modified form thereof.
6. The therapeutic agent according to claim 4 or 5, wherein the antibody is monoclonal antibodies.
7. The therapeutic agent according to claim 4 or 5, wherein the antibody is a humanized or chimeric antibody.
8. The therapeutic agent according to claim 7, wherein the humanized antibody is humanized 23-57-137-1 antibody.
9. The therapeutic agent according to any one of claims 1 to 8, wherein the dental disease is caused by hypercalcemia.
10. The therapeutic agent according to any one of claims 1 to 9, wherein the dental disease is developed concurrently with carcinoma.
11. A preventive agent for dental diseases, which comprises, as an active ingredient, a substance inhibiting the binding between parathyroid hormone related peptide (PTHrP) and a receptor thereof.
12. The preventive agent according to claim 11, wherein the dental disease is at least one member selected from a group consisting of abnormal calcification on dentin andor dental pulp, thinning of dentin, basophilic dentin, dentin dysplasia, and dentinogenesis imperfecta.
13. The preventive agent according to claim 11 or 12, wherein the substance is an antagonist for the PTHrP receptor.
14. The preventive agent according to claim 11 or 12, wherein the substance is an anti-PTHrP antibody.
15. The preventive agent according to claim 11 or 12, wherein the substance is a fragment of an anti-PTHrP antibody andor a modified form thereof.
16. The preventive agent according to any one of claims 11 to 15, wherein the dental disease is caused by hypercalcemia.
17. The preventive agent according to any one of claims 11 to 16, wherein the dental disease is developed concurrently with carcinoma.